Teva Divests Takeda JV, Pivots To Innovative Drugs In Japan

Takeda Expects $365m Payment

 
• By Lisa Takagi

The divestment decision comes years after it slimmed down amid challenges in the Japanese generic market.

Teva decided to divest Takeda JV (Shutterstock)

More from Strategy

More from Generics Bulletin